Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Combine and conquer: handling biotech combination inventions in the wake of KSR

Nature Biotechnology volume 27, pages 446–448 (2009)Cite this article

To what extent will KSR limit combination inventions in biotech?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. KSR International Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007).

  2. Yamanaka, M. Nat. Biotechnol. 26, 1085–1086 (2008).

    Article  CAS  Google Scholar 

  3. Pfizer v. Apotex, 480 F.3d 1348 (Fed. Cir. 2007).

  4. Eisai Co. v. Dr. Reddy's Labs. Ltd. 533 F.3d 1353 (Fed. Cir. 2008).

  5. Graham v. John Deere Co. of Kansas City, 383 US 1 (1966).

  6. KSR v. Teleflex, 127 S. Ct. at 1739–1743.

  7. KSR v. Teleflex, 127 S. Ct. at 1741.

  8. In re Sullivan, 498 F.3d 1345 (Fed. Cir. 2007).

  9. In re Sullivan, 498 F.3d at 1353.

  10. Innogenetics NV v. Abbott Labs., 512 F.3d 1363 (Fed. Cir. 2008).

  11. Innogenetics NV v. Abbott Labs., 512 F.3d at 1373.

  12. Pharmastem Therapeutics v. Viacell, 491 F.3d 1342 (Fed. Cir. 2007).

  13. Pharmastem Therapeutics v. Viacell, 491 F.3d at 1363.

  14. Pharmastem Therapeutics v. Viacell, 491 F.3d at 1360.

  15. Pharmastem Therapeutics v. Viacell, 491 F.3d at 1374–1378.

  16. Pharmastem Therapeutics v. Viacell, 491 F.3d at 1378.

  17. Innogenetics v. Abbott Labs., 512 F.3d at 1373.

  18. KSR v. Teleflex, 127 S. Ct. at 1742.

  19. Pharmastem Therapeutics v. Viacell, 491 F.3d at 1363.

Download references

Acknowledgements

H.K.W. thanks his parents, Sie Ting and Prapasri, his sister, Meelynn, and his wife, Joanne Kong, for their unconditional love and support. He dedicates this piece to his grandmother Tangon Thanesuan, his grandaunt Dorothy Hwang, and his mother-in-law, Esther Soo Kong, who continue to inspire him to think creatively and believe in what is right. You will never be forgotten.

Author information

Authors and Affiliations

  1. Ha Kung Wong and Dana Lau are at Fitzpatrick, Cella, Harper & Scinto, New York, New York, USA. hwong@fchs.com,

    Ha Kung Wong & Dana Lau

Authors
  1. Ha Kung Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dana Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, H., Lau, D. Combine and conquer: handling biotech combination inventions in the wake of KSR. Nat Biotechnol 27, 446–448 (2009). https://doi.org/10.1038/nbt0509-446

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0509-446

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing